West Pharmaceutical Services (WST) Cut to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of West Pharmaceutical Services (NYSE:WST) from a buy rating to a hold rating in a research note issued to investors on Thursday morning.

According to Zacks, “West Pharmaceutical Services, Inc. is a global drug delivery technology company that applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines and consumer healthcare products. West is the world’s premiere provider of standard-setting systems and device components for parenterally administered medicines and an emerging leader in the development of advanced formulation technologies for the transmucosal delivery of drugs. West contract manufacturing harnesses a powerful combination of innovation, technology, infrastructure and expertise to serve the pharmaceutical, medical and consumer industries. Along with more than 50 years of experience, they bring customers quality, safety and reliability in injection molding, contract assembly and finished packaging. “

Separately, ValuEngine upgraded shares of West Pharmaceutical Services from a hold rating to a buy rating in a report on Wednesday, October 17th.



Shares of NYSE:WST opened at $101.13 on Thursday. West Pharmaceutical Services has a 12 month low of $82.74 and a 12 month high of $125.09. The company has a current ratio of 2.67, a quick ratio of 1.94 and a debt-to-equity ratio of 0.15. The firm has a market cap of $7.44 billion, a P/E ratio of 36.38, a P/E/G ratio of 3.44 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, October 25th. The medical instruments supplier reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.70 by $0.06. West Pharmaceutical Services had a net margin of 9.06% and a return on equity of 15.97%. The business had revenue of $431.70 million for the quarter, compared to analyst estimates of $427.55 million. Research analysts predict that West Pharmaceutical Services will post 2.8 earnings per share for the current fiscal year.

In related news, SVP Karen Flynn sold 20,458 shares of the firm’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $116.23, for a total transaction of $2,377,833.34. Following the sale, the senior vice president now directly owns 31,051 shares in the company, valued at $3,609,057.73. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.90% of the company’s stock.

Several large investors have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in shares of West Pharmaceutical Services by 1.4% during the second quarter. BlackRock Inc. now owns 6,570,782 shares of the medical instruments supplier’s stock worth $652,413,000 after acquiring an additional 87,586 shares during the period. USS Investment Management Ltd raised its holdings in shares of West Pharmaceutical Services by 24.6% during the second quarter. USS Investment Management Ltd now owns 1,087,078 shares of the medical instruments supplier’s stock worth $107,936,000 after acquiring an additional 214,707 shares during the period. Hermes Investment Management Ltd. raised its holdings in shares of West Pharmaceutical Services by 4.8% during the second quarter. Hermes Investment Management Ltd. now owns 968,945 shares of the medical instruments supplier’s stock worth $96,207,000 after acquiring an additional 44,169 shares during the period. Bessemer Group Inc. raised its holdings in shares of West Pharmaceutical Services by 13,849.8% during the second quarter. Bessemer Group Inc. now owns 950,816 shares of the medical instruments supplier’s stock worth $94,407,000 after acquiring an additional 944,000 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of West Pharmaceutical Services by 27.1% during the second quarter. Janus Henderson Group PLC now owns 875,723 shares of the medical instruments supplier’s stock worth $86,951,000 after acquiring an additional 186,752 shares during the period. Institutional investors and hedge funds own 93.63% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: What is a Stop Order?

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply